BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34408521)

  • 1. A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.
    Glembotsky AC; De Luca G; Heller PG
    J Blood Med; 2021; 12():719-732. PubMed ID: 34408521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome.
    Sims MC; Mayer L; Collins JH; Bariana TK; Megy K; Lavenu-Bombled C; Seyres D; Kollipara L; Burden FS; Greene D; Lee D; Rodriguez-Romera A; Alessi MC; Astle WJ; Bahou WF; Bury L; Chalmers E; Da Silva R; De Candia E; Deevi SVV; Farrow S; Gomez K; Grassi L; Greinacher A; Gresele P; Hart D; Hurtaud MF; Kelly AM; Kerr R; Le Quellec S; Leblanc T; Leinøe EB; Mapeta R; McKinney H; Michelson AD; Morais S; Nugent D; Papadia S; Park SJ; Pasi J; Podda GM; Poon MC; Reed R; Sekhar M; Shalev H; Sivapalaratnam S; Steinberg-Shemer O; Stephens JC; Tait RC; Turro E; Wu JKM; Zieger B; ; Kuijpers TW; Whetton AD; Sickmann A; Freson K; Downes K; Erber WN; Frontini M; Nurden P; Ouwehand WH; Favier R; Guerrero JA
    Blood; 2020 Oct; 136(17):1956-1967. PubMed ID: 32693407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal megakaryocyte development and platelet function in Nbeal2(-/-) mice.
    Kahr WH; Lo RW; Li L; Pluthero FG; Christensen H; Ni R; Vaezzadeh N; Hawkins CE; Weyrich AS; Di Paola J; Landolt-Marticorena C; Gross PL
    Blood; 2013 Nov; 122(19):3349-58. PubMed ID: 23861251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NBEAL2 mutations and bleeding in patients with gray platelet syndrome.
    Pluthero FG; Di Paola J; Carcao MD; Kahr WHA
    Platelets; 2018 Sep; 29(6):632-635. PubMed ID: 29869935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice.
    Deppermann C; Cherpokova D; Nurden P; Schulz JN; Thielmann I; Kraft P; Vögtle T; Kleinschnitz C; Dütting S; Krohne G; Eming SA; Nurden AT; Eckes B; Stoll G; Stegner D; Nieswandt B
    J Clin Invest; 2013 Jul; 123(8):3331-42. PubMed ID: 23863626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Nbeal2(-/-) mouse as a model for the gray platelet syndrome.
    Deppermann C; Nurden P; Nurden AT; Nieswandt B; Stegner D
    Rare Dis; 2013; 1():e26561. PubMed ID: 25003009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gray Platelet Syndrome Presenting With Pancytopenia, Splenomegaly, and Bone Marrow Fibrosis.
    Tariq H; Perez Botero J; Higgins RA; Medina EA
    Am J Clin Pathol; 2021 Jul; 156(2):253-258. PubMed ID: 33586768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune dysregulation, autoimmunity, and granule defects in gray platelet syndrome.
    Collins JH; Mayer L; Guerrero Lopez JA
    J Thromb Haemost; 2023 Jun; 21(6):1409-1419. PubMed ID: 37028650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patients.
    Di Buduo CA; Alberelli MA; Glembostky AC; Podda G; Lev PR; Cattaneo M; Landolfi R; Heller PG; Balduini A; De Candia E
    Sci Rep; 2016 Mar; 6():23213. PubMed ID: 26987485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NBEAL2 is required for neutrophil and NK cell function and pathogen defense.
    Sowerby JM; Thomas DC; Clare S; Espéli M; Guerrero JA; Hoenderdos K; Harcourt K; Marsden M; Abdul-Karim J; Clement M; Antrobus R; Umrania Y; Barton PR; Flint SM; Juss JK; Condliffe AM; Lyons PA; Humphreys IR; Chilvers ER; Ouwehand WH; Dougan G; Smith KG
    J Clin Invest; 2017 Sep; 127(9):3521-3526. PubMed ID: 28783043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endoplasmic reticulum protein SEC22B interacts with NBEAL2 and is required for megakaryocyte α-granule biogenesis.
    Lo RW; Li L; Pluthero FG; Leung R; Eto K; Kahr WHA
    Blood; 2020 Aug; 136(6):715-725. PubMed ID: 32384141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gray platelet syndrome: proinflammatory megakaryocytes and α-granule loss cause myelofibrosis and confer metastasis resistance in mice.
    Guerrero JA; Bennett C; van der Weyden L; McKinney H; Chin M; Nurden P; McIntyre Z; Cambridge EL; Estabel J; Wardle-Jones H; Speak AO; Erber WN; Rendon A; Ouwehand WH; Ghevaert C
    Blood; 2014 Dec; 124(24):3624-35. PubMed ID: 25258341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-granule biogenesis: from disease to discovery.
    Chen CH; Lo RW; Urban D; Pluthero FG; Kahr WH
    Platelets; 2017 Mar; 28(2):147-154. PubMed ID: 28277061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and α-granule deficiency.
    Bottega R; Pecci A; De Candia E; Pujol-Moix N; Heller PG; Noris P; De Rocco D; Podda GM; Glembotsky AC; Cattaneo M; Balduini CL; Savoia A
    Haematologica; 2013 Jun; 98(6):868-74. PubMed ID: 23100277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Megakaryocytic emperipolesis and platelet function abnormalities in five patients with gray platelet syndrome.
    Larocca LM; Heller PG; Podda G; Pujol-Moix N; Glembotsky AC; Pecci A; Alberelli MA; Balduini CL; Landolfi R; Cattaneo M; De Candia E
    Platelets; 2015; 26(8):751-7. PubMed ID: 25806575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil specific granule and NETosis defects in gray platelet syndrome.
    Aarts CEM; Downes K; Hoogendijk AJ; Sprenkeler EGG; Gazendam RP; Favier R; Favier M; Tool ATJ; van Hamme JL; Kostadima MA; Waller K; Zieger B; van Bergen MGJM; Langemeijer SMC; van der Reijden BA; Janssen H; van den Berg TK; van Bruggen R; Meijer AB; Ouwehand WH; Kuijpers TW
    Blood Adv; 2021 Jan; 5(2):549-564. PubMed ID: 33496751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous 8bp Deletion in Nbeal2 Recapitulates the Gray Platelet Syndrome in Mice.
    Tomberg K; Khoriaty R; Westrick RJ; Fairfield HE; Reinholdt LG; Brodsky GL; Davizon-Castillo P; Ginsburg D; Di Paola J
    PLoS One; 2016; 11(3):e0150852. PubMed ID: 26950939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules.
    Gunay-Aygun M; Falik-Zaccai TC; Vilboux T; Zivony-Elboum Y; Gumruk F; Cetin M; Khayat M; Boerkoel CF; Kfir N; Huang Y; Maynard D; Dorward H; Berger K; Kleta R; Anikster Y; Arat M; Freiberg AS; Kehrel BE; Jurk K; Cruz P; Mullikin JC; White JG; Huizing M; Gahl WA
    Nat Genet; 2011 Jul; 43(8):732-4. PubMed ID: 21765412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nbeal2 interacts with Dock7, Sec16a, and Vac14.
    Mayer L; Jasztal M; Pardo M; Aguera de Haro S; Collins J; Bariana TK; Smethurst PA; Grassi L; Petersen R; Nurden P; Favier R; Yu L; Meacham S; Astle WJ; Choudhary J; Yue WW; Ouwehand WH; Guerrero JA
    Blood; 2018 Mar; 131(9):1000-1011. PubMed ID: 29187380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet α-granules modulate the inflammatory response under systemic lipopolysaccharide injection in mice.
    Tariket S; Guerrero JA; Garraud O; Ghevaert C; Cognasse F
    Transfusion; 2019 Jan; 59(1):32-38. PubMed ID: 30394544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.